Reviva Pharmaceuticals Holdings Inc (RVPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.90. The fair price of Reviva Pharmaceuticals Holdings Inc (RVPH) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.23

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Reviva Pharmaceuticals Holdings Inc (RVPH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Reviva Pharmaceuticals Holdings Inc (RVPH) has a current Price-to-Book (P/B) ratio of 6.56. Compared to its 3-year average P/B ratio of 0.07, the current P/B ratio is approximately 9561.77% higher. Relative to its 5-year average P/B ratio of 1.71, the current P/B ratio is about 283.29% higher. Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward Free Cash Flow (FCF) yield of approximately -78.21%. Compared to its 3-year average FCF yield of -52.96%, the current FCF yield is approximately 47.68% lower. Relative to its 5-year average FCF yield of -44.87%, the current FCF yield is about 74.32% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RVPH competitors is 3.82, providing a benchmark for relative valuation. Reviva Pharmaceuticals Holdings Inc Corp (RVPH.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RVPH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RVPH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RVPH currently overvalued or undervalued?

What is Reviva Pharmaceuticals Holdings Inc (RVPH) fair value?

RVPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Reviva Pharmaceuticals Holdings Inc (RVPH) is between to according to relative valuation method.

How does RVPH's valuation metrics compare to the industry average?

The average P/S ratio for RVPH's competitors is 3.82, providing a benchmark for relative valuation. Reviva Pharmaceuticals Holdings Inc Corp (RVPH) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Mar 03 2026?

As of Mar 03 2026, Reviva Pharmaceuticals Holdings Inc (RVPH) has a P/B ratio of 6.56. This indicates that the market values RVPH at 6.56 times its book value.

What is the current FCF Yield for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Mar 03 2026?

As of Mar 03 2026, Reviva Pharmaceuticals Holdings Inc (RVPH) has a FCF Yield of -78.21%. This means that for every dollar of Reviva Pharmaceuticals Holdings Inc's market capitalization, the company generates -78.21 cents in free cash flow.

What is the current Forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Mar 03 2026?

As of Mar 03 2026, Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward P/E ratio of -0.89. This means the market is willing to pay $-0.89 for every dollar of Reviva Pharmaceuticals Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Reviva Pharmaceuticals Holdings Inc (RVPH) as of Mar 03 2026?

As of Mar 03 2026, Reviva Pharmaceuticals Holdings Inc (RVPH) has a Forward P/S ratio of 0.00. This means the market is valuing RVPH at $0.00 for every dollar of expected revenue over the next 12 months.

RVPH Valuation